Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Establishing a Reasonable Price for an Orphan Drug
1 July 2018
The high cost of drugs for rare diseases (‘orphan drugs’) has generated considerable debate. While there is debate in the economic literature over whether a premium…
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
1 July 2018
Using a multidisciplinary methodological approach combining a theoretical economic framework with uptake/market share analyses by country and interviews, this OHE research concludes that: (i) IP incentives…
The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
5 January 2018
The notion that the price of a medicine should be linked in some way to value it generates for patients and the health system is generally…
A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”
1 May 2018
This OHE Consulting Report reviews “Estimated costs of production and potential prices of medicines for the World Health Organization Essential Medicines List” (Hill et al., 2018)…
The UK Biotech Sector and Brexit: Past Performance and Future Prospects
1 April 2018
This seminar briefing examines (1) why the UK has not produced large biotech firms that develop drugs, similar to those in the United States (US), (2)…
Barriers to Uptake of Minimal Access Surgery in the United Kingdom
1 March 2018
Surgical practice has and continues to develop at a tremendous pace, reflecting the evolving technological landscape as well as the expanding skillset of the surgical workforce.…
Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
1 January 2018
The CRA Report has an underlying assumption that the EU is as globally competitive in generics and biosimilars as it is in innovative products. There is…
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
This report analyses patient access in the UK to new medicines authorised via the centralised procedure between 2011 and 2016.
Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
12 December 2017
This report explores the consequences of the exit of the United Kingdom (UK) from the European Union (EU) on public health in the UK and in…